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 Abstract 
 A direct relationship has been established between synaptic 
activity and amyloid- β secretion. Dysregulation of neuronal 
calcium homeostasis was shown to increase production of 
amyloid- β , contributing to the initiation of Alzheimer ’ s dis-
ease. Among the different routes of Ca 2 +  entry,  N -methyl-
 d -aspartate (NMDA) receptors, a subtype of ionotropic 
glutamate receptors, are especially involved in this process 
because of their ability to gate high levels of Ca 2 +  infl ux. 
These receptors have been extensively studied for their 
crucial roles in synaptic plasticity that underlies learning 
and memory but also in neurotoxicity occurring during 
acute brain injuries and neurodegenerative diseases. For 
one decade, several studies provided evidence that NMDA 
receptor activation could have distinct consequences on 
neuronal fate, depending on their location. Synaptic NMDA 
receptor activation is neuroprotective, whereas extrasynap-
tic NMDA receptors trigger neuronal death and/or neuro-
degenerative processes. Recent data suggest that chronic 
activation of extrasynaptic NMDA receptors leads to a sus-
tained neuronal amyloid- β release and could be involved 
in the pathogenesis of Alzheimer ’ s disease. Thus, as for 
other neurological diseases, therapeutic targeting of extra-
synaptic NMDA receptors could be a promising strategy. 
Following this concept, memantine, unlike other NMDA 
receptor antagonists was shown, to preferentially target the 
extrasynaptic NMDA receptor signaling pathways, while 
relatively sparing normal synaptic activity. This molecular 
mechanism could therefore explain why memantine is, to 
date, the only clinically approved NMDA receptor antago-
nist for the treatment of dementia. 
 Keywords:  amyloid- β ;  amyloid precursor protein; 
 Alzheimer ’ s disease;  calcium;  memantine;  NMDA receptors. 
 Introduction 
 Alzheimer ’ s disease (AD) is a chronic disorder that slowly 
destroys neurons leading to progressive cognitive disability. If 
the etiology of AD is largely unknown, the neuropathological 
hallmarks of the disease are well characterized. They include 
an extracellular deposition of diffuse and neuritic plaques 
composed of amyloid- β (A β ) peptide, an intracellular accrual 
of neurofi brillary tangles of hyperphosphorylated micro-
tubule-associated protein TAU, synaptic dysfunctions and 
a selective neuronal loss (Selkoe , 2001 ). These histopatho-
logical lesions do not occur diffusely throughout the brain 
parenchyma but are particularly restricted to the cortex, hip-
pocampus and amygdale (Selkoe and Shenk , 2003 ). Although 
neurofi brillary tangles are commonly found in diverse neuro-
degenerative diseases, amyloid plaques are only a hallmark 
of AD. Thus, the leading candidate for the trigger of AD is 
supposed to be the A β peptide which is produced by the pro-
teolytic processing of the amyloid precursor protein (APP) 
(Hardy and Selkoe , 2002 ). Its primacy has been manifested in 
the well known  ‘ amyloid-cascade hypothesis ’ (Citron , 2004 ). 
This hypothesis suggested that the mismetabolism of APP was 
the initiating event in AD pathogenesis, subsequently leading 
to disruption of synaptic connections as well as the aggrega-
tion of A β , specifi cally A β 42 (Hardy and Allsop , 1991 ; Tanzi 
and Bertram , 2005 ). Among the different causes proposed 
to explain the increased production of A β , dysregulation of 
neuronal calcium homeostasis was fi rst postulated more than 
20  years ago (Khachaturian , 1987, 1989, 1994 ). This theory 
was supported by experimental studies showing alterations in 
calcium signaling both in sporadic and in familial cases of 
AD (Mattson , 2004 ; Smith et al. , 2005 ; Stutzmann , 2005 ). 
Comparatively to other routes of Ca 2 +  entry in neuronal 
cells,  N -methyl- d -aspartate receptors (NMDARs), a subtype 
of ionotropic glutamate receptors, are of particular interest 
because of their special ability to gate high levels of Ca 2 +  
infl ux (Choi et al. , 1988 ; Sattler et al. , 1998 ). These receptors 
have been extensively studied for their crucial role in synap-
tic plasticity and excitotoxicity (Rothman and Olney , 1995 ; 
Waxman and Lynch , 2005 ). Moreover, excessive NMDAR 
activity was shown to contribute importantly to the etiology 
of many acute or chronic neurodegenerative disorders such 
as stroke, Hungtinton ’ s disease, HIV-associated dementia and 
AD (Lipton and Rosenberg , 1994 ; Lancelot and Beal , 1998 ). 
Several studies reported a direct link between NMDAR over-
activation on the one hand, and APP processing and neuronal 
A β secretion on the other hand, even if the conclusions could 
be somewhat different (Lesn é et al., 2005 ; Marcello et al. , 
2007 ; Hoey et al. , 2009 ). It was further demonstrated that the 
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cellular location of NMDARs is a key parameter controlling 
their effect on neuronal viability. While activation of synaptic 
NMDARs was shown to drive neuroprotective gene transcrip-
tion and to promote neuron survival, stimulation of extrasyn-
aptic NMDARs triggers neuronal death (Hardingham et al., 
 2002 ;  L é veill é et al., 2008 ). In the same way, this dichoto-
mous nature of NMDAR signaling has also been outlined in 
the fi eld of neurological disorders (Hardingham and Bading , 
2010 ). Recently, our group provided data suggesting that per-
turbations in the balance between synaptic and extrasynap-
tic NMDAR activity could increase neuronal A β production, 
contributing to the pathogenesis of AD (Bordji et al. , 2010 ). 
 The present review focuses on the relationship between 
NMDAR activation and neuronal A β production. We outline 
the role of this subtype of glutamate receptors in calcium dys-
regulation which seems to be central to the pathogenesis of 
AD. Finally, from the available data, we examine prospects 
for therapies using memantine, the only clinically approved 
NMDAR antagonist for the treatment of AD. 
 APP metabolism and A β formation 
 Around 25  years ago, the A β peptide was fi rst recognized 
to be derived from its large APP, by sequential endoprote-
olytic cleavage (Kang et al. , 1987 ). APP is a type-1 mem-
brane glycoprotein found at the cell surface, in endosomal, 
endoplasmic reticulum and Golgi membranes in many cell 
types. The protein is encoded by the  APP gene located on 
chromosome 21. Individuals with Down ’ s syndrome, who 
have three copies of chromosome 21, and hence three copies 
of the  APP gene, develop clinical and pathological signs of 
early-onset Alzheimer ’ s. Several possible neuronal functions 
have been ascribed to APP holoprotein and/or their secreted 
soluble derivatives (sAPP α ) (Qiu et al. , 1995 ). sAPP α acts 
as an autocrine factor (Saitoh et al. , 1989 ) and can exhibit 
some neuroprotective or neurotrophic properties (Mattson 
et al. , 1993 ). The function of APP is unclear and deletion of 
the  APP gene in mice results in neither early mortality nor 
appreciable morbidity. This absence of vital consequence of 
APP deletion could be explained by the expression of closely 
related proteins, the amyloid precursor-like proteins (APLP1 
and APLP2). More recent  in vitro studies reported that APP 
might be an axonal transport receptor and might function in 
cellular interactions when inserted at the plasma membrane 
(Kamal et al. , 2000 ; Stokin and Goldstein , 2006 ). The pro-
tein was also suggested to be involved in the activation of 
G-protein-dependent pathway (Nishimoto et al. , 1993 ), lead-
ing to apoptosis activation (Mbebi et al. , 2002 ). Moreover, 
the cytoplasmic carboxyl-terminal domain of APP has been 
shown to be transported to the nucleus to modulate calcium 
signaling, underlying its role in signal transduction (Cao and 
Sudhof , 2001; Leissring et al., 2002 ). 
 The processing of APP takes place according to the general 
pattern of regulated intramembrane proteolysis. It undergoes 
two consecutive endoproteolytic cleavages that either pre-
clude or cause the formation of the amyloidogenic A β peptide 
(Selkoe , 2001 ). In a fi rst step, the extracellular part of APP is 
cleaved from the cell surface, either by  α - or  β -secretase. Three 
members of the ADAM family (a disintegrin- and metallopro-
teinase family enzyme) ADAM9, ADAM10 and ADAM17 
have been shown to display  α -secretase activity (Lammich 
et al. , 1999 ). The prevalent cutting of APP by  α -secretase 
precludes A β formation as the cleavage site is localized 
inside the amyloid sequence between residues 16 and 17. 
This enzymatic action leads to the release of a large soluble 
extracellular amino terminal fragment of APP (sAPP α ) and 
of a non-amyloidogenic 83-amino acid C-terminal fragment 
(C83). Conversely, in an amyloidogenic pathway, APP could 
be alternatively cleaved at a position located 99 amino acids 
from the C-terminus by a  β -secretase, an aspartyl protease 
known as BACE1 ( β -site APP-cleaving enzyme) (Hussain et 
al. , 1999 ). Cleavage by  β -secretase releases a slightly shorter 
soluble APP peptide (sAPP β ) in the extracellular space and 
leaves a 99-amino acids C-terminal fragment (C99) within the 
membrane. In a second step of APP proteolysis, C83 or C99 
are cleaved by  γ -secretase within the lipid bilayer to generate, 
respectively, the release of the non-amyloidogenic p3 peptide 
or of the 40 – 42 amino acid residues long A β . This intramem-
brane cleavage is a rather unusual cellular process and it was 
initially found to be impossible at a biochemical level (Steiner 
and Haass , 2000 ). The  γ -secretase has been identifi ed to be a 
high-molecular weight active complex composed of preseni-
lin 1 or 2 (PS1 and PS2), nicastrin, anterior pharynx-defective 
phenotype (aph-1) and PS-enhancer (PEN-2) (Francis et al. , 
2002 ). The A β 1 – 42 variant exhibits higher hydrophobic prop-
erties than A β 1 – 40 and thus is more susceptible to be involved 
in fi bril formation. Indeed, the longer isoform is primarily 
found in the diffuse and neuritic plaques. Conversely, A β 1 – 42 
represents only approximately 10 % of the total A β species 
produced in the brain parenchyma, whereas A β 1 – 40 is the more 
abundant isoform released following APP processing (Haass , 
2004 ). 
 It was shown that A β production was a normal cellular 
process because it was detected in cerebrospinal fl uid and 
plasma of healthy subjects throughout life. One pivotal ques-
tion, still open, is to know at which state A β peptides begin to 
become pathological. Accumulation of A β in cerebral tissues 
of AD patients could be the result of an impaired clearance 
of the peptide and/or its overproduction through an altered 
processing of APP. Thus, all phenomena that cause pertur-
bations of APP processing, linked or not to calcium infl ux, 
could modify A β generation and play a central role in AD 
pathogenesis. 
 Neuronal activity, APP metabolism and 
A β production 
 For many years, AD was attributed to the deposit of fi brillar 
A β which causes the generation of neurofi brillar tangles and 
ultimately the death of neurons. In a more recent version of 
the amyloid cascade hypothesis, it is proposed that soluble 
A β oligomers are responsible for the early cognitive decline 
in AD (Walsh and Selkoe , 2007 ). Thus, extensive studies 
have shown that these oligomers rapidly disrupt synaptic 
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functions progressively leading to synaptic loss and neuronal 
death (Shankar et al. , 2007 ). In the same way, they were also 
described to inhibit long-term potentiation and to facilitate 
long-term depression (Li et al. , 2009 ). There is now ample 
evidence that A β oligomers do not affect neuronal viabil-
ity directly but interfere specifi cally with synaptic function. 
In patients suffering from AD, memory impairment or loss 
strongly correlates with cortical levels of soluble A β species, 
especially oligomers. 
 If the role of APP in calcium signaling and the effects of 
A β on synaptic dysfunction and loss have been thoroughly 
documented, there are much less data on how neuronal 
activity could modulate neuronal APP metabolism and 
transport, and extracellular A β release. The fi rst study to 
show that A β formation can be increased by calcium infl ux 
through calcium channels of the plasma membrane, or cal-
cium release from endoplasmic reticulum stores was by 
Querfurth and Selkoe  (1994) . Then, several other reports 
provided circumstantial evidence suggesting that, in both 
animal models and humans, A β levels could be related to 
synaptic activity. First, using positron emission tomogra-
phy and functional magnetic resonance imaging, it was 
evidenced that the highest A β accumulation and aggrega-
tion occurs in brain regions exhibiting elevated metabolic 
activity at rest, such as hippocampus and parts of frontal 
and parietal cortex (Buckner et al. , 2005 ). High metabolic 
activity is generally well correlated to high neuronal activi-
ties. Second, a relationship has been reported between 
stress, neuronal activity and AD. Patients that are prone 
to psychological distress are more likely to develop AD. 
A signifi cantly higher A β level was also measured in the 
interstitial fl uid (ISF) of APP transgenic mice subjected to 
restraint stress when compared to the corresponding animal 
controls (Palop et al. , 2007 ). Finally, some patients suffer-
ing from temporal lobe epilepsy, thus exhibiting substan-
tially elevated neuronal activity, were shown to develop 
diffuse A β deposits in these regions of the brain very early 
in life (Mackenzie and Miller , 1994 ). 
 More recently, different investigators interestingly reported 
that synaptic activity modulates A β metabolism. Kamenetz 
and coworkers demonstrated that increased synaptic activ-
ity enhanced the formation and secretion of A β peptide in 
hippocampal slice neurons (Kamenetz et al. , 2003 ). In turn, 
A β selectively depresses excitatory synaptic transmission 
onto neurons that overexpress APP as well as nearby neu-
rons that do not. This depression can be reversed by blockade 
of neuronal activity, especially using NMDAR antagonists, 
demonstrating the involvement of this subtype of receptor. 
Additionally, they propose that activity-dependent modula-
tion of endogenous A β production could normally participate 
in a feedback that could keep neuronal hyperactivity in check. 
Disruption of this feedback system could contribute to dis-
ease progression in AD. 
 In another  in vivo study, Cirrito and coworkers used a 
microdialysis technique in tandem with concurrent hip-
pocampal electrophysiological recording to assess whether 
there are dynamic changes in ISF A β levels in conjunction 
with different levels of neuronal activity in awake, behaving 
mice (Cirrito et al. , 2005 ). They demonstrated that A β levels 
in the brain ISF are dynamically and directly infl uenced by 
synaptic activity on a timescale of minutes to hours. When 
synaptic activity within the hippocampus was increased by 
electrically stimulating the perforant pathway, A β in ISF 
increased by 30 % within 1  h. Conversely, administration 
of the sodium channel blocker tetrodotoxin, which causes a 
cessation of neuronal activity, signifi cantly decreased basal 
electrophysiological activity and subsequently dropped A β 
levels in ISF by 40 % . This effect was shown to be reversible, 
demonstrating a direct relationship between neuronal activity 
and A β concentration in ISF. 
 In a more recent study performed by the same group, evi-
dence was provided showing that synaptic activity causes 
an increase in vesicle endocytosis, driving more APP in the 
endocytotic compartment, ultimately resulting in increased 
neuronal A β production and release (Cirrito et al. , 2008 ). 
 Because extracellular A β is known to reduce synaptic 
plasticity and alter synaptic function, then increased secre-
tion of A β induced by synaptic activity could lead to dam-
age and loss of synapses and to progressive accumulation 
of extracellular A β into amyloid plaques, which are impor-
tant hallmarks of AD. The consequence of this point of 
view is that synaptic activity is paradoxically detrimental 
and could contribute to AD pathogenesis. This seems to be 
in contradiction with another set of studies supporting the 
concept that cognitive activity could be protective against 
AD. Higher educational level or involvement in mentally 
stimulating activities correlated with a lower probability of 
developing AD (Stern , 2006 ). Behavior studies performed 
with AD transgenic mice demonstrated that environmen-
tal enrichment reduced A β levels and amyloid deposition 
(Lazarov et al. , 2005 ). 
 In fact, the results of these different studies are confl icting 
in appearance. In both  in vitro and  in vivo experiments with 
activity-induced secretion, the concentration of extracellular 
A β remains in the picomolar range. This concentration range 
of A β was also measured in the ISF of mice subjected to 
a circadian rhythm, with more elevated levels when awake 
(Kang et al. , 2009 ). Moreover, other authors reported that A β 
levels in the picomolar range enhanced synaptic plasticity 
and memory (Puzzo et al. , 2008 ; Garcia -Osta and Alberini, 
2009 ). Thus, these data support the idea that A β secretion 
could be a physiological event occurring with normal brain 
activity. 
 Tampellini et al. recently underlined the important role of 
intraneuronal A β in the pathogenesis of AD (Tampellini and 
Gouras , 2010 ). They showed that KCl-induced synaptic activ-
ity reduced intraneuronal A β and protects against A β -related 
synaptic alterations. Neprilysin is involved in the intracellu-
lar A β decrease and, by live cell imaging, they evidence the 
transport of APP to synapses promoted by synaptic activity 
(Tampellini et al. , 2009 ). 
 Taken together, these reports demonstrate a lack of con-
sensus concerning the effect of neuronal activity (electrical, 
synaptic or channel-dependent) on A β synthesis and release. 
Important parameters seem to be intracytosolic calcium 
levels and the method of calcium entry in neurons. 
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 NMDAR activation and neuronal A β synthesis 
 Numerous studies demonstrated that excessive Ca 2 +  entry 
leading to neuronal Ca 2 +  overload is a key early step in gluta-
mate-induced cell death in excitotoxic processes (Choi , 1995 ). 
Among the different routes of calcium entry, NMDARs, a 
subtype of ionotropic glutamate receptors, are of particular 
interest because of their special ability to gate high levels of 
Ca 2 +  infl ux (Rothman and Olney , 1995 ). Thus, these receptors 
have been extensively studied for their crucial role in syn-
aptic plasticity and neuronal damage occurring during acute 
or chronic pathologies (Waxman and Lynch , 2005 ). Dennis 
Choi was the fi rst to demonstrate that the NMDARs were 
the primary source of toxic Ca 2 +  infl ux mediating glutamate 
excitotoxicity (Choi et al. , 1988 ). Shortly afterwards, it was 
proposed that Ca 2 +  entry through NMDARs was particularly 
effective at killing neurons as compared with entry through 
other channels (Tymianski et al. , 1993 ). At the same time, 
there was circumstantial evidence pointing to a role for glu-
tamate toxicity and NMDAR activity in acute brain injuries 
(stroke, traumatism) or in chronic neurodegenerative diseases, 
including Huntington ’ s disease (Choi et al. , 1988 ; Lipton and 
Rosenberg , 1994 ; Rothman and Olney , 1995 ). The involve-
ment of glutamate mediated neurotoxicity in the pathogenesis 
of AD is now widely accepted. Central to this hypothesis is 
the assumption that glutamate receptors, especially NMDARs, 
are continuously overactivated. Such mild and chronic activa-
tion leads to impairment of synaptic plasticity (learning) and 
ultimately to synapse loss and neuronal death. 
 For several years, we have studied in the lab the link existing 
between NMDAR activation, APP processing and neuronal 
A β production. We initially demonstrated that a prolonged 
stimulation of cortical neuron cultures with a sublethal con-
centration of NMDA increased the production and secretion 
of A β (Lesn é et al., 2005 ). This effect was preceded by an 
important modifi cation of neuronal APP expression pattern 
with the expression of an APP isoform which is normally 
absent in neurons: the Kunitz protease inhibitor (KPI) domain 
containing APP (KPI-APP). This KPI domain was found to 
associate with the  α -secretase candidate tumor necrosis 
factor- α converting enzyme (TACE) and to inhibit its enzy-
matic activity. The consequence of this KPI-dependent inhibi-
tion is a shift from  α -secretase to  β -secretase-mediated APP 
processing and then to an increase in A β production. These 
results suggested that even mild deregulation of the gluta-
matergic neurotransmission could increase A β production 
and represent a causal risk for developing AD. It is important 
to note that the effect reported in this study, with a long-last-
ing NMDAR activation period, refl ected a pathophysiological 
situation. Indeed, the observed effects (induction of KPI-APP 
expression followed by A β production) were due to transcrip-
tional changes in the APP isoforms expressed in neuronal cul-
tures after prolonged (24  h) NMDAR stimulation. 
 At another level, some authors have recently investi-
gated whether NMDAR activation could directly modulate 
APP processing in primary neuron cultures by analyzing the 
release of soluble APP (sAPP) and APP C-terminal fragments 
as a refl ection of  α - and  β -secretase activities. They found that 
NMDAR stimulation, after glutamate or NMDA treatment, 
increased non-amyloidogenic  α -secretase-mediated APP pro-
cessing (Hoey et al. , 2009 ). This effect was accompanied by 
a signifi cant decrease in neuronal A β release. Importantly, 
only NMDAR antagonists D-AP5 and MK801 blocked 
the modifi cations on APP and A β metabolism, in contrast 
to the AMPA receptor antagonist CNQX or the  l -type cal-
cium channel blocker nifedipine. The authors proposed that 
NMDAR-mediated inhibition of A β release is a secondary 
event resulting from increased  α -secretase-mediated cleav-
age of APP. It has previously been reported that there is a 
competition between the candidate  α -secretases ADAM10 
and ADAM17 and  β -secretase for APP cleavage (Skovronsky 
et al. , 2000 ). Thus, an increase in  α -secretase-mediated APP 
cleavage during NMDAR stimulation could limit the amount 
of APP available for BACE1 cleavage, reducing neuronal A β 
production. 
 A close relationship between NMDAR stimulation and 
 α -secretase activity has been previously underlined in primary 
hippocampal neurons. Marcello et al. reported that synapse-
associated protein-97, a protein involved in dynamic traffi ck-
ing of proteins to the excitatory synapse, drives ADAM10 
to the postsynaptic membrane in dendritic spines (Marcello 
et al. , 2007 ). Interestingly, they demonstrated that NMDAR 
activity directly mediates this event and positively modulates 
 α -secretase activity. Their fi ndings reinforce the concept that 
the glutamatergic synapse, especially its NMDAR subcom-
ponent, can intrinsically express a mechanism leading to a 
shift of APP metabolism towards a non-amyloidogenic path-
way. It should be noted that other receptor systems have been 
shown to promote the non-amyloidogenic pathway. In stud-
ies performed in animal models or in human, activation of 
muscarinic M1 acetylcholine receptors has been reported to 
increase  α -secretase cleavage of APP and to decrease A β lev-
els in cerebrospinal fl uid (Nitsch et al. , 2000 ; Caccamo et al. , 
2006 ). The same observations have been made after mGluR1 α 
glutamate receptor activation. Other authors showed that 
electrical depolarization as well as protein kinase C activation 
induces sAPP α production in rat hippocampal slices (Caputi 
et al. , 1997 ). 
 Whereas the involvement of NMDARs in the excitotoxic 
process is well established, one should consider that the sur-
vival of several types of neurons is strongly dependent on syn-
aptic NMDAR activity and function. Elimination of NMDAR 
activity  in vivo causes widespread apoptosis and exacerbates 
neuron loss when applied after traumatic brain injury or dur-
ing ongoing neurodegeneration. Thus, although high levels 
of NMDAR activity can be harmful, so too is blockade of 
normal synaptic NMDAR activity. This  ‘ NMDAR paradox ’ 
explains why the use of NMDAR antagonists is somewhat 
unsuccessful and has failed in clinical trials. 
 For several years, it was well accepted that only the degree 
of Ca 2 +  entry through NMDARs could account for these 
differences in cell fate: moderate NMDAR activity was 
considered to be benefi cial for neurons, whereas excessive 
stimulation with subsequent neuronal Ca 2 +  overload was del-
eterious. This point of view was gradually challenged over 
the past decade in light of several important papers reporting 
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that NMDAR activation could have opposite consequences 
on neuronal viability, according to their cellular localization 
(synaptic vs. extrasynaptic sites). Stimulation of synaptic 
NMDARs induces prosurvival events by triggering genomic 
processes that render neurons more resistant to apopto-
sis and oxidative insults. Conversely, calcium fl ux through 
extrasynaptic NMDARs overrides these pathways, causing 
mitochondrial dysfunction and cell death (Hardingham et 
al. , 2002 ). According to this concept, it is not only the level 
of intra cellular calcium concentration that confers neuronal 
toxicity, but rather the Ca 2 +  infl ux through NMDARs located 
outside the synapse. Moreover, several studies have dem-
onstrated that some of the extrasynaptic signaling pathways 
dominate over effects of synaptic signaling, shutting off some 
important aspects such as cAMP response element-binding 
(CREB) protein and the extracellular signal-regulated kinase 
cascade (Ivanov et al. , 2006 ). Conversely, for other authors, 
toxic stimuli through NMDARs are uniformly characterized 
by an obligatory link to massive mitochondrial Ca 2 +  loading, 
whatever receptor location (Stanika et al. , 2009 ). If the bases 
for differences between synaptic and extrasynaptic NMDAR 
signaling are still outstanding questions, the mechanism of 
excitotoxicity has been reviewed in the light of these new 
data. 
 Excitotoxicity has been described as a mechanism leading 
to neuronal death and was widely described in acute neu-
ronal injuries such as trauma and stroke (Choi et al. , 1988 ; 
Rothman and Olney , 1995 ). However, it is also an important 
feature of neurodegenerative diseases. For example, it was 
suggested that excessive NMDAR activity contributes to the 
pathogenesis of Huntington ’ s disease, a disorder character-
ized by degeneration of striatal medium-sized spiny neurons. 
It is worth noting that NMDAR-dependent plasticity and 
transmission are altered in Huntington ’ s disease transgenic 
mice much before the onset of motor defi cits. Two important 
recent papers provided strong arguments suggesting that the 
balance between synaptic and extrasynaptic NMDAR activ-
ity could be crucial in determining neuronal cell survival in 
Huntington ’ s disease (Okamoto et al. , 2009 ; Milnerwood et 
al. , 2010 ). These studies were performed on YAC128 trans-
genic mice expressing mutant full-length human huntingtin 
(mtHTT) protein that contains a 128-length polyglutamine 
expansion. Data clearly indicate increased NR2B-containing 
extrasynaptic NMDARs in the striatum of transgenic mice. 
Therefore, augmented extrasynaptic NMDAR signaling is 
detected at ages preceding motor dysfunction and neuronal 
loss. As mentioned before, extrasynaptic NMDAR activity 
is coupled to a CREB-inactivating dephosphorylation sig-
nal. Consistent with this, CREB phosphorylation levels are 
reduced in the striatum of YAC128 mice. 
 The fact that a direct link was revealed between sus-
tained NMDAR activation and neuronal A β production 
(see above) led us to investigate the relative part of the two 
pools of NMDARs in this synthesis. Thus, we recently stud-
ied the infl uence of a selective stimulation of both popula-
tions of receptors on APP metabolism and A β production 
(Bordji et al. , 2010 ). In primary cultures of cortical neurons, 
prolonged stimulation of extrasynaptic, but not synaptic, 
NMDARs importantly increased the neuronal production of 
A β . This effect was preceded by a shift from APP695 (the 
neuronal isoform of APP) to KPI-APPs, isoforms exhibiting 
an important amyloidogenic potential. By contrast, no induc-
tion of KPI-APP expression and no increase in neuronal A β 
synthesis were observed after synaptic NMDAR activation. 
Interestingly, intracellular calcium concentration measured 
after extrasynaptic NMDAR activation was lower than after 
synaptic activation. Thus, the modifi cations observed on APP 
and A β metabolism cannot be explained by a higher calcium 
entry but rather suggest distinct signaling pathways for each 
pool of receptors. Indeed, changes in neuronal APP expression 
pattern mediated by extrasynaptic NMDAR activation was 
regulated at an alternative splicing level involving calcium/
calmodulin-dependent protein kinase IV. A major fi nding of 
this study is that a deregulation of the glutamatergic neu-
rotransmission involving extrasynaptic NMDARs increases 
levels of neuronal A β synthesis. Thus, this could represent 
a causal risk for developing AD by promoting accumulation 
of this pathological protein, one of the principal hallmarks 
of the disease. 
 Taken together, these data demonstrate that NMDAR over-
stimulation is a common feature of various acute and chronic 
neurological disorders such as AD. By contrast, this subtype 
of glutamate receptors is known to mediate important physi-
ological neural functions. They also indicate that, in addition 
to the stimulus intensity that will determine the level of neu-
ronal calcium infl ux, the location of the NMDARs is a crucial 
parameter for determining neuronal consequences. Thus, to 
avoid unwanted adverse side effects, the ideal therapy would 
selectively block excessive NMDAR activity without affect-
ing its physiological and neuroprotective roles. Therefore, 
one promising strategy is to selectively target extrasynaptic 
NMDAR signaling while sparing synaptic signaling. 
 Targeting extrasynaptic NMDARs to lower A β 
peptide: interest of memantine 
 For many years, excitotoxicity, and especially the NMDAR 
contribution, has represented a particularly attractive thera-
peutic target because it is implicated in the pathophysiology 
of a wide variety of acute and chronic neurodegenerative 
disorders. However, the unique relation between NMDAR 
overactivation and neuronal death is challenged by their par-
allel role in neuronal plasticity and neurotrophic processes 
(Hardingham , 2006 ; Hetman and Kharebava , 2006 ). Thus, 
to date, NMDAR antagonists that showed promise as inhibi-
tors of excitotoxicity also blocked normal synaptic func-
tions. Consequently, they had severe and unacceptable side 
effects explaining the failure of these drugs in clinical trials 
(Ikonomidou and Turski , 2002 ). However, one molecule, 
identifi ed in the early 1990s as a NMDAR antagonist, was 
shown to be effective for the treatment of AD with an excel-
lent clinical safety profi le: memantine (Chen et al. , 1992 ). 
Memantine is an uncompetitive, open-channel blocker with 
strong voltage dependency and a relatively rapid off-rate from 
the channel (Lipton , 2006 ). To date, it is the only clinically 
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approved NMDAR antagonist for the treatment of moderate-
to-severe forms of AD (2002 in Europe; 2003 in the USA) 
(Chen and Lipton , 2006 ; Parsons et al. , 2007 ). Memantine was 
shown to slow the cognitive decline associated with AD after 
as little as 2  weeks of treatment (Johnson and Kotermanski , 
2006 ). Because of the defi cit in the cholinergic system in the 
brain of AD patients, the major alternative therapies in AD are 
all acetylcholinesterase inhibitors that also act on peripheral 
cholinergic synapses. The different properties of memantine 
allow the drug to limit pathological activity of the NMDARs 
while relatively sparing normal synaptic activity. In fact, dif-
ferent independent papers reported that, unlike other classical 
NMDAR antagonists (e.g., MK801, AP5), memantine prefer-
entially blocks extrasynaptic over synaptic NMDAR currents 
in neurons ( L é veill é et al., 2008 ; Xia et al. , 2010 ). The impor-
tance of maintaining normal synaptic NMDA signaling has 
been interestingly underlined by Papadia et al. who showed 
that synaptic NMDA activity is necessary to boost intrinsic 
antioxidant defenses (Papadia et al. , 2008 ). 
 Using calcium imaging analysis, we have demonstrated in 
primary cortical neuron cultures that memantine signifi cantly 
blocked extrasynaptic NMDAR response ( L é veill é et al., 
2008 ). This induced neuroprotection against excitotoxicity 
triggered by NMDA bath treatment. The fact that memantine 
does not affect synaptic NMDAR response is in accordance 
with previous results showing that memantine only acts under 
pathological activation of NMDARs, without affecting nor-
mal synaptic neurotransmission (Lipton , 2007 ). This phar-
macological feature could explain the favorable safety profi le 
of this compound in its clinical use in humans. 
 The Lipton group fi rst reported that memantine binds at or 
near the Mg 2 +  site in the NMDAR-associated channel and they 
recently provided evidence explaining the discriminative action 
of memantine (Xia et al. , 2010 ). Under normal conditions, at 
resting membrane potentials, most NMDARs are blocked by 
extracellular Mg 2 +  , which occupies the channel. Conversely, 
under pathological conditions, the ion channel is continuously 
open and Mg 2 +  block is mostly relieved. Therefore, memantine 
at low doses (up to 10  µ m ) predominantly acts as an open-
channel blocker in the presence of prolonged elevation of 
gluta mate concentration, as seen for extrasynaptic receptors, 
but is relatively inactive when glutamate is elevated for only 
milliseconds, as in synaptic transmission. 
 The effi cacy of memantine to antagonize neurodegenera-
tive pathways has been elegantly demonstrated in the context 
of Hungtinton ’ s disease pathology in recent  in vivo studies 
(Okamoto et al. , 2009 ; Milnerwood et al. , 2010 ). Given the 
link evidenced between NMDAR dysregulation and AD 
(see above), it seemed pertinent to evaluate the capacity of 
memantine to modulate A β release in  in vitro and/or  in vivo 
models. In fact, memantine has been previously shown to pro-
tect hippocampal cells from the neurotoxic effects of A β 1 – 40 
in rats and to improve spatial learning in transgenic mice 
overexpressing mutated human APP and PS1 (Scholtzova 
et al. , 2008 ; Song et al. , 2008 ). However, scarce data are 
available showing that memantine could modulate the pro-
duction of A β . A study recently reported that memantine 
alone, at therapeutically relevant concentrations (1 – 4  µ m ), 
signifi cantly lowered the levels of sAPP and A β 1 – 40 in human 
neuroblastoma cells (SK-N-SH) (Alley et al. , 2010 ). Because 
this undifferentiated cell line has been shown to express no 
detectable NMDAR activity, it was therefore concluded that 
the mechanism by which memantine acts on SK-N-SH cells 
is likely to be NMDAR independent. Two days treatment of 
primary rat cortical neuronal cultures with the same concen-
trations of memantine led to a decrease in the potentially amy-
loidogenic A β 1 – 42 secretion. Here again, the age of the culture 
(7  days) was not suffi cient for neurons to express functional 
NMDARs. Therefore, the observed reduction of A β 1 – 42 by 
memantine within 2  days post-treatment in primary cultures 
suggests a non-NMDAR-mediated mechanism. In APP/PS1 
transgenic mice exhibiting high brain levels of A β 1 – 42 , oral 
administration of memantine (20  mg/kg/day for 8  days) pro-
duced a plasma drug concentration of 0.96  µ m and signifi -
cantly reduced the cortical levels of soluble A β 1 – 42 . The ratio 
of A β 1 – 40 /A β 1 – 42 also increased in treated mice, suggesting a 
combination of mechanisms that could bypass the NMDAR 
and act on the  γ -secretase complex. In complement to these 
fi ndings, long-term treatments (4  months) of a different APP/
PS1 transgenic mouse model with memantine (10  mg/kg/day; 
intraperitoneal) have shown signifi cant reduction of amyloid 
plaques in these animals. This suggests that memantine can 
rapidly reduce A β production, although longer term treat-
ments are required to alter insoluble A β plaques. 
 In a recent study, we have evidenced a direct relationship 
between prolonged extrasynaptic NMDAR activation and 
neuronal A β production (Bordji et al. , 2010 ). The release of 
A β was preceded by the neuronal induction of KPI-APPs, 
isoforms exhibiting an important amyloidogenic potential. 
Taking into account previous data of our group, a mechanism 
was therefore proposed to establish the link between an over-
production of A β and a deregulation of the glutamatergic neu-
rotransmission involving NMDAR activation (Figure  1 ). We 
further showed that memantine dose dependently inhibited 
extrasynaptic NMDAR-induced KPI-APP protein expression 
as well as neuronal A β 1 – 42 release. Interestingly, these effects 
were observed at a clinically achievable concentration (1  µ m ), 
after a prolonged time of activation (24  h), thus refl ecting a 
pathophysiological situation. This is in accordance with pre-
vious observations reporting that memantine only acts under 
pathological conditions without much affecting normal func-
tions, and thus relatively spares normal excitatory synaptic 
activity (Lipton , 2007 ). Because of the impossibility to adapt 
 in vivo a protocol of extrasynaptic NMDAR activation, these 
 in vitro data were partially confi rmed in animal studies. 
NMDA intraperitoneal injections increased cortical KPI-APP 
expression in mice, whereas low-dose memantine, described 
to block extrasynaptic NMDAR, signifi cantly inhibited KPI-
APP induction. 
 Conclusion 
 Calcium ions play crucial roles in neuronal cell functions such 
as synaptic plasticity, membrane excitability and gene expres-
sion. If tau and A β are identifi ed as the causative factors for 
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the disease, there is accumulating evidence pointing to the 
importance of disturbed calcium signaling in AD pathogen-
esis. Aging, especially linked to the development of AD, also 
involves signifi cant changes in calcium homeostasis, which 
could contribute to the initiation of the disease. Both fi brillar 
A β and A β oligomers were shown to have deleterious effects 
on synaptic function and neuronal fate in the context of AD. 
Thus, accumulation of A β outside the cell but also intracel-
lularly, within synapses, is a major event of AD pathogen-
esis. Several studies have provided evidence that synaptic 
activity modulates A β production and calcium entry through 
NMDARs was identifi ed as a major component in the con-
trol of neuronal A β synthesis. Very recently, the extrasynap-
tic pool of NMDARs has been identifi ed to be involved in 
the pathogenesis of neurodegenerative diseases. In AD, pro-
longed extrasynaptic NMDAR activation induces increased 
neuronal A β release. Memantine, a well-tolerated drug that 
has already been approved for clinical use, was shown to 
preferentially target extrasynaptic NMDARs and to lower 
A β synthesis. Thus, targeting the extrasynaptic pool of recep-
tors could importantly contribute to the clinical effi ciency 
and tolerability of memantine. However, very few studies 
reporting such effects in the fi eld of AD have been published. 
Other mechanisms, perhaps NMDAR-independent and that 
could affect  β - and/or  γ -secretase activities, are not excluded. 
Therefore, further studies need to be performed to investigate 
the pathogenic pathways that could link NMDAR dysregu-
lation and A β overexpression and the precise mechanism of 
action of memantine. 
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